Emerald Health Therapeutics announced it completed an investment deal worth 2.5 million into Northern Vine Canada in order to get 53 percent of the company and appoint three of its four directors.

Emerald Health Therapeutics (TSXV:EMH OTCQX:EMHTF) announced it completed an investment deal worth 2.5 million into Northern Vine Canada in order to get 53 percent of the company and appoint three of its four directors.
As quoted in the press release:

Abattis Bioceuticals Corp. (“Abattis”) (CSE:ATT) (OTC:ATTBF) will continue to hold the remaining 47% of Northern Vine.
Northern Vine is a Licensed Dealer (“LD”) under the provisions of the Canadian Controlled Drugs and Substances Act. An LD is permitted to carry out certain business activities that Emerald is not permitted to undertake as a Licensed Producer (“LP”) under Access to Cannabis for Medical Purpose Regulations (“ACMPR”). Health Canada recently renewed Northern Vine’s dealer license. Northern Vine’s laboratory facility is located in Langley, British Columbia.
LD status permits not only exporting and importing of cannabis, as LPs are permitted to do under ACMPR, but also exporting and importing of cannabis oils.

Click here to read the full press release.

Source: globenewswire.com

abattis abattis bioceuticals british columbia canada health health canada licensed producer lp oils regulations Cannabis Investing